|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Day One Biopharmaceuticals, Inc. (DAWN) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
87,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co. is engaged in developing and commercializing targeted therapies for patients with genomically-defined cancers. Co.'s main product candidate, DAY101 (tovorafenib), is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. Co.'s second product candidate, pimasertib, is an oral, highly-selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the RAS/mitogen-activated protein kinase pathway.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,244,684 |
4,978,018 |
| Total Buy Value |
$0 |
$0 |
$24,978,318 |
$65,978,328 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
4 |
7 |
| Total Shares Sold |
225,453 |
235,538 |
246,104 |
4,525,329 |
| Total Sell Value |
$3,837,225 |
$3,955,119 |
$4,100,690 |
$62,122,635 |
| Total People Sold |
4 |
4 |
4 |
8 |
| Total Sell Transactions |
14 |
18 |
25 |
103 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Takeda Ventures, Inc. |
10% Owner |
– – • |
2021-12-03 |
4 |
S |
$18.47 |
$231,189 |
I/I |
(12,517) |
6,515,089 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2021-12-01 |
4 |
AS |
$16.62 |
$172,242 |
D/D |
(10,000) |
1,376,718 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2021-10-22 |
4 |
GA |
$0.00 |
$0 |
I/I |
1,000,000 |
1,000,000 |
|
- |
|
| Blackman Samuel C. |
Chief Medical Officer |
• – – |
2021-10-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,000,000 |
1,386,718 |
|
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2021-06-01 |
4 |
B |
$16.00 |
$14,000,000 |
D/D |
875,000 |
9,377,776 |
2.44 |
- |
|
| Blavatnik Len |
Affiliate of 10% Owner |
– – – |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,502,776 |
8,502,776 |
|
- |
|
| Papanek Julie |
Director |
– • – |
2021-06-01 |
4 |
B |
$16.00 |
$208,000 |
I/I |
13,000 |
10,735,645 |
2.1 |
- |
|
| Papanek Julie |
Director |
– • – |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
7,476,776 |
10,722,645 |
|
- |
|
| Atlas Venture Associates Xi, Llc |
10% Owner |
– – • |
2021-06-01 |
4 |
B |
$16.00 |
$8,000,000 |
I/I |
500,000 |
250,000 |
1.5 |
- |
|
| Atlas Venture Associates Xi, Llc |
10% Owner |
– – • |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
I/I |
8,502,776 |
741,396 |
|
- |
|
| Canaan Partners Xi Llc |
10% Owner |
– – • |
2021-06-01 |
4 |
B |
$16.00 |
$208,000 |
D/D |
13,000 |
10,735,645 |
2.45 |
- |
|
| Canaan Partners Xi Llc |
10% Owner |
– – • |
2021-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,476,776 |
10,722,645 |
|
- |
|
| Becker Daniel J. |
Director |
– • – |
2021-06-01 |
4 |
B |
$16.00 |
$80,000 |
D/D |
5,000 |
5,000 |
2.39 |
- |
|
| Josey John A. |
Director |
– • – |
2021-06-01 |
4 |
B |
$16.00 |
$112,000 |
D/D |
7,000 |
72,292 |
2.39 |
- |
|
| York Charles N Ii |
COO, CFO and SecretaryOfficer |
• – – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
337,560 |
|
- |
|
| Josey John A. |
Director |
– • – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
65,292 |
|
- |
|
| Holles Natalie C. |
Director |
– • – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
57,310 |
|
- |
|
| Papanek Julie |
|
– – – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,245,869 |
|
- |
|
| Papanek Julie |
|
– – – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
465,000 |
|
- |
|
| Bender Jeremy |
Chief Executive OfficerOfficer |
• • – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,828,838 |
|
- |
|
| Blackman Samuel C. |
Chief Medical OfficerOfficer |
• – – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,386,718 |
|
- |
|
| Ramasastry Saira |
Director |
– • – |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,485 |
|
- |
|
| Millennium Pharmaceuticals Inc |
10% Owner |
– – • |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
6,470,382 |
|
- |
|
| Canaan Partners Xi Llc |
10% Owner |
– – • |
2021-05-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,245,869 |
|
- |
|
174 Records found
|
|
Page 7 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
